DOI: 10.1001/jama.2026.11253 ISSN: 0098-7484

CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences

Rachel E. Sachs, Kristi Martin

This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ (CMS) extension of the Medicare Glucagon-Like Peptide-1 (GLP-1) Bridge and outlines unanswered questions related to how the bridge will affect Medicare.

More from our Archive